Petros Pharmaceuticals 将来の成長

Future 基準チェック /26

Petros Pharmaceuticalsは、33.6%と39.8%でそれぞれ年率33.6%で利益と収益が成長すると予測される一方、EPSはgrowで45.2%年率。

主要情報

33.6%

収益成長率

45.2%

EPS成長率

Pharmaceuticals 収益成長	23.7%
収益成長率	39.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	11 Sep 2024

今後の成長に関する最新情報

更新なし

Recent updates

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Nov 13

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Aug 15

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Jul 28

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Dec 07

業績と収益の成長予測

NasdaqCM:PTPI - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	5	-13	N/A	N/A	1
12/31/2025	5	-13	N/A	N/A	1
12/31/2024	5	-17	N/A	N/A	1
9/30/2024	4	-20	-6	-6	N/A
6/30/2024	4	-21	-9	-9	N/A
3/31/2024	5	-20	-8	-8	N/A
12/31/2023	6	-14	-8	-8	N/A
9/30/2023	7	-13	-7	-7	N/A
6/30/2023	4	-22	-5	-5	N/A
3/31/2023	6	-21	-8	-8	N/A
12/31/2022	6	-20	-13	-13	N/A
9/30/2022	4	-24	-20	-20	N/A
6/30/2022	8	-12	-19	-19	N/A
3/31/2022	6	-12	-17	-17	N/A
12/31/2021	8	-9	-12	-12	N/A
9/30/2021	12	-6	-8	-8	N/A
6/30/2021	13	-8	-10	-10	N/A
3/31/2021	12	-11	-13	-13	N/A
12/31/2020	10	-21	-15	-15	N/A
9/30/2020	9	-24	-11	-11	N/A
6/30/2020	10	-29	-9	-9	N/A
3/31/2020	12	-32	-1	-1	N/A
12/31/2019	16	-33	2	3	N/A
12/31/2018	14	-32	6	8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PTPI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PTPI今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PTPI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PTPIの収益 ( 39.8% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: PTPIの収益 ( 39.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PTPIの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Petros Pharmaceuticals 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Petros Pharmaceuticals, Inc. Announces Board Resignations

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2024

Petros Pharmaceuticals, Inc. Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Petros Pharmaceuticals, Inc. Announces Results of First of Series of Pivotal Studies Aimed at Facilitating FDA-Approved OTC Access of STENDRA (Avanafil) for Consumers

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R) (Avanafil)

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA (avanafil) as it Pursues OTC Status

Insufficient new directors

Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

Petros Pharmaceuticals, Inc., Annual General Meeting, Dec 29, 2023

Petros Pharmaceuticals, Inc. announced delayed 10-Q filing

Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label

Second quarter 2023 earnings released: US$1.20 loss per share (vs US$0.88 loss in 2Q 2022)

Petros Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.084 loss in 1Q 2022)

Third quarter 2022 earnings released: US$0.67 loss per share (vs US$0.17 loss in 3Q 2021)

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Expansion of FDA Labeling for Its Oral Erectile Dysfunction Drug, STENDRA

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 29, 2022

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.22 loss in 2Q 2021)

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Petros Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.008 loss per share (vs US$0.31 profit in 1Q 2021)

Petros Pharmaceuticals, Inc. Announces They Will Be Pursuing the 505(B)(2) Pathway for Its Investigational Agent

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Positive Results of Over-The-Counter (Otc) Label Comprehension Study for Erectile Dysfunction Drug STENDRA

Full year 2021 earnings released: US$0.82 loss per share (vs US$3.86 loss in FY 2020)

Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug Stendra (Avanafil)

Petros Pharmaceuticals, Inc. announced that it has received $2.200023 million in funding

Petros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.299978 million.

Petros Pharmaceuticals, Inc. announced that it expects to receive $2.200023 million in funding

Petros Pharmaceuticals Announces Positive Over-the-Counter Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.96 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.22 loss per share (vs US$1.68 loss in 2Q 2020)

Petros Pharmaceuticals, Inc. Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment

Petros Pharmaceuticals, Inc.(NasdaqCM:PTPI) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: EPS US$0.31 (vs US$1.77 loss in 1Q 2020)

New 90-day low: US$3.22

Petros Pharmaceuticals Appoints Dr. Mohit Khera to Steering Committee

Petros Pharmaceuticals, Inc. Appoints Mitchell Arnold to Serve as the Principal Financial Officer and Principal Accounting Officer

Petros Pharmaceuticals, Inc. Announces Executive Changes

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘